Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR IVABRADINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ivabradine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00143507 ↗ The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Completed Institut de Recherches Internationales Servier Phase 3 2004-12-01 The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.
NCT00202566 ↗ Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris Completed Institut de Recherches Internationales Servier Phase 3 2005-06-01 To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris
NCT00202579 ↗ Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure Completed Institut de Recherches Internationales Servier Phase 2 2004-09-01 To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure
NCT00757055 ↗ If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure Withdrawn St Vincent's University Hospital, Ireland Phase 2 2012-12-01 The purpose of this study is to investigate whether the medicine ivabradine, a novel drug which slows the heart rate has a favourable effect on patients with diastolic heart failure. Ivabradine is a specific heart rate-lowering agent. It has a licence for treating patients with angina who are intolerant of agents such as beta blockers or whose angina is not adequately controlled. It has been shown to prolong exercise tolerance in these patients and to reduce the frequency of chest pain. Its mechanism of action is felt to be purely due to reducing heart rate, by as much as 10 beats per minute at rest, as well as by reducing the heart rate response to exercise. Patients with diastolic heart failure often complain of breathlessness on exertion which relates to the stiffness or lack of compliance of their heart i.e. the heart fails to relax rapidly enough to allow it to fill with blood between each heart beat. This may result in high pressure in the heart chamber which backs up in to the lungs and may be experienced as breathlessness. There is little evidence that any specific therapy benefits patients with this type of heart failure besides treating coexisting problems such as high blood pressure or angina. By slowing the heart rate down with ivabradine, the heart would have a longer time to fill during exercise which would make it more effective. This slowing of the heart rate may therefore relieve the breathlessness experienced on activity such as walking to the shops or up a flight of stairs etc.
NCT00815100 ↗ Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Completed Hospital Universitario de Canarias Phase 4 2009-04-01 The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ivabradine Hydrochloride

Condition Name

Condition Name for Ivabradine Hydrochloride
Intervention Trials
Heart Failure 13
Coronary Artery Disease 6
Atrial Fibrillation 5
Chronic Heart Failure 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ivabradine Hydrochloride
Intervention Trials
Heart Failure 31
Myocardial Ischemia 12
Coronary Artery Disease 11
Coronary Disease 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ivabradine Hydrochloride

Trials by Country

Trials by Country for Ivabradine Hydrochloride
Location Trials
United States 24
China 11
Italy 11
United Kingdom 6
Egypt 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ivabradine Hydrochloride
Location Trials
Michigan 3
Ohio 2
New York 2
Illinois 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ivabradine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ivabradine Hydrochloride
Clinical Trial Phase Trials
Phase 4 33
Phase 3 16
Phase 2/Phase 3 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ivabradine Hydrochloride
Clinical Trial Phase Trials
Completed 28
Unknown status 21
Recruiting 15
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ivabradine Hydrochloride

Sponsor Name

Sponsor Name for Ivabradine Hydrochloride
Sponsor Trials
Institut de Recherches Internationales Servier 6
Amgen 6
Second University of Naples 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ivabradine Hydrochloride
Sponsor Trials
Other 106
Industry 11
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Dow
Moodys
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.